V

Viracta Therapeutics, Inc.

46 employees

Viracta Therapeutics is a precision oncology company focused on new treatment of virus-associated malignancies.

Basic info

Industry

biotechnology research

Sectors

Biotechnology
Epstein-Barr Virus
Lymphoproliferative Disorders
lymphoma
Immuno-Oncology
Pharmaceutical
Breast Cancer
Health Care
Therapeutics
Gastric Cancer
Medical
Biopharma

Date founded

2007

Funding rounds raised

Total raised

$65M

from 23 investors over 23 rounds

V

Viracta Therapeutics, Inc. raised $50M on November 5, 2021

Investors: Oxford Finance LLC

V

Viracta Therapeutics, Inc. raised $65M on February 24, 2021

Investors: Sectoral Asset Management, aMoon Fund, Logos Global Management, LP, LifeSci Venture Partners, Ridgeback Capital Management LLC, Surveyor Capital and Samsara BioCapital

V

Viracta Therapeutics, Inc. raised undisclosed on November 30, 2020

Investors: LifeSci Venture Partners, aMoon Fund and Taiwania Capital

V

Viracta Therapeutics, Inc. raised undisclosed on October 28, 2019

Investors: Taiwania Capital

V

Viracta Therapeutics, Inc. raised $10M on December 4, 2018

Investors: Shenzhen Salubris Pharmaceuticals Co.,LTD

V

Viracta Therapeutics, Inc. raised $18M on April 4, 2017

Investors: Forward Ventures and NantKwest (NASDAQ: NK)

V

Viracta Therapeutics, Inc. raised $13M on March 12, 2012

Investors: Aberdare Ventures, Forward Ventures and Lilly Ventures

V

Viracta Therapeutics, Inc. raised $12M on April 21, 2010

Investors: Forward Ventures, Lilly Ventures and Aberdare Ventures

V

Viracta Therapeutics, Inc. raised $20M on November 2, 2007

Investors: Forward Ventures and Lilly Ventures

FAQ